期刊
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
卷 77, 期 2, 页码 332-336出版社
ELSEVIER
DOI: 10.1016/j.ejpb.2010.12.016
关键词
Haloperidol; Polymeric nanocapsules; Extrapyramidal effects; Motor disorders; Vacuous chewing movement; Catalepsy
资金
- CNPq
- CAPES
- PRPGP (Pro-Reitoria de Pos-Graduacao e Pesquisa)
- PROAP-UFSM
Haloperidol is an antipsychotic drug associated with the development of movement disorders. We evaluated the effect of its nanoencapsulation on its pharmacological activity and motor side effects. Haloperidol-loaded polysorbate-coated nanocapsules (H-NC) showed nanometric size, negative zeta potential and low polydispersity indices and high encapsulation efficiency (>95%). Rats received a single dose of H-NC (0.2 mg/kg ip) and four doses of D,L-amphetamine, AMPH (8.0 mg/kg ip), injected every 3 h (0, 3, 6 and 9 h). The AMPH-induced stereotyped movements were quantified in the intervals of 15 min after each of four doses of AMPH, demonstrating greater pharmacological efficacy of the H-NC over free haloperidol (FH). The acute motor side effects were evaluated 1 h after a single dose of H-NC or its free solution (0.2 mg/kg ip). The group treated with H-NC presented lower extrapyramidal effects (catalepsy and oral dyskinesia) than those treated with FH. In the last experimental set, rats sub-chronically treated with a daily dose of H-NC (0.2 mg/kg ip) for 28 days showed a lower incidence of extrapyramidal effects than those treated with the free drug (0.2 mg/kg ip). Our findings showed the potential of using H-NC in the development of a nanomedicine aimed at increasing the efficacy of this antipsychotic drug and reducing its side effects. (C) 2010 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据